---
schema_version: "secwatch.filing_event.v1"
accession: "0001459839-26-000054"
form_type: "8-K"
ticker: "SIBN"
cik: "0001459839"
company_name: "SI-BONE, Inc."
filed_at: "2026-05-11T20:11:38+00:00"
generated_at: "2026-05-11T20:16:24.229240+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# SI-BONE Q1 revenue $52.6M (+11%), net loss improves 33.8%; raises FY26 guidance

## Summary
- Worldwide revenue $52.6M (+11.2% YoY); US revenue $49.3M (+10.0%), international $3.3M (+33.9%).
- Net loss $4.3M (-33.8% YoY, -$0.10 diluted EPS); adjusted EBITDA $2.5M (vs $0.5M, >440% improvement).
- Gross margin stable at 79.8%; operating loss improved 31.9% to $5.1M.
- Raised FY2026 revenue guidance to $230-233M (prior $228.5-232.5M); gross margin ~79% (prior ~78%).
- Operational: over 1,650 active US physicians (+17%); CMS proposes new MS-DRG for complex spinal fusion with iFuse Bedrock Granite.

## SEC filing metadata
- accession: 0001459839-26-000054
- form_type: 8-K
- ticker: SIBN
- cik: 0001459839
- company_name: SI-BONE, Inc.
- filed_at: 2026-05-11T20:11:38+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1459839/000145983926000054/0001459839-26-000054-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1459839/000145983926000054/sibn-20260511.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001459839-26-000054
- JSON: https://secwatch.observer/filing/0001459839-26-000054.json
- Plain text: https://secwatch.observer/filing/0001459839-26-000054.txt

## Key facts
- Earnings Releases
  SI-BONE, Inc. reported quarter ended March 31, 2026 results: revenue $52.6 million, net income $4.3 million, EPS $0.10 per diluted share. Guidance raised.
  - Period: quarter ended March 31, 2026
  - Revenue: $52.6 million
  - Net income: $4.3 million
  - EPS: $0.10 per diluted share
  - Guidance: raised
  - Result: reported results
  source text: physician engagement and ~440% improvement in adjusted EBITDA First Quarter 2026 Financial Highlights (all comparisons are to the prior year period) • Worldwide revenue of $52.6 million, representing growth of 11.2% • U.S. revenue of $49.3 million, representing growth of 10.0% • Gross margin of 79.8% • Net loss of $4.3 million, representing an improvement of
  evidence_url: https://www.sec.gov/Archives/edgar/data/1459839/000145983926000054/0001459839-26-000054-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.